Display options
Cite
Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy?. Drugs. 2008;68(15):2131-62doi: 10.2165/00003495-200868150-00005.
Krentz, A. J., Patel, M. B., & Bailey, C. J. (2008). New drugs for type 2 diabetes mellitus: what is their place in therapy?. Drugs, 68(15), 2131-62. https://doi.org/10.2165/00003495-200868150-00005
Krentz, Andrew J, et al. "New drugs for type 2 diabetes mellitus: what is their place in therapy?." Drugs vol. 68,15 (2008): 2131-62. doi: https://doi.org/10.2165/00003495-200868150-00005
Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy?. Drugs. 2008;68(15):2131-62. doi: 10.2165/00003495-200868150-00005. PMID: 18840004.
Copy Download .nbib Format: NLM
Share it on

Drugs. 2008;68(15):2131-62. doi: 10.2165/00003495-200868150-00005.

New drugs for type 2 diabetes mellitus: what is their place in therapy?.

Drugs

Andrew J Krentz, Mayank B Patel, Clifford J Bailey

Affiliations

  1. Department of Diabetes and Endocrinology, Southampton University Hospitals and University of Southampton, Southampton, UK. [email protected]

PMID: 18840004 DOI: 10.2165/00003495-200868150-00005

Abstract

Oral therapy for type 2 diabetes mellitus, when used appropriately, can safely assist patients to achieve glycaemic targets in the short to medium term. However, the progressive nature of type 2 diabetes usually requires a combination of two or more oral agents in the longer term, often as a prelude to insulin therapy. Issues of safety and tolerability, notably weight gain, often limit the optimal application of anti-diabetic drugs such as sulfonylureas and thiazolidinediones. Moreover, the impact of different drugs, even within a single class, on the risk of long-term vascular complications has come under scrutiny. For example, recent publication of evidence suggesting potential detrimental effects of rosiglitazone on myocardial events generated a heated debate and led to a reduction in use of this drug. In contrast, current evidence supports the view that pioglitazone has vasculoprotective properties. Both drugs are contraindicated in patients who are at risk of heart failure. An additional recently identified safety concern is an increased risk of fractures, especially in postmenopausal women.Several new drugs with glucose-lowering efficacy that may offer certain advantages have recently become available. These include (i) injectable glucagon-like peptide-1 (GLP-1) receptor agonists and oral dipeptidyl peptidase-4 (DPP-4) inhibitors; (ii) the amylin analogue pramlintide; and (iii) selective cannabinoid receptor-1 (CB1) antagonists. GLP-1 receptor agonists, such as exenatide, stimulate nutrient-induced insulin secretion and reduce inappropriate glucagon secretion while delaying gastric emptying and reducing appetite. These agents offer a low risk of hypoglycaemia combined with sustained weight loss. The DPP-4 inhibitors sitagliptin and vildagliptin are generally weight neutral, with less marked gastrointestinal adverse effects than the GLP-1 receptor agonists. Potential benefits of GLP-1 receptor stimulation on beta cell neogenesis are under investigation. Pancreatitis has been reported in exenatide-treated patients. Pramlintide, an injected peptide used in combination with insulin, can reduce insulin dose and bodyweight. The CB1 receptor antagonist rimonabant promotes weight loss and has favourable effects on aspects of the metabolic syndrome, including the hyperglycaemia of type 2 diabetes. However, in 2007 the US FDA declined approval of rimonabant, requiring more data on adverse effects, notably depression. The future of dual peroxisome proliferator-activated receptor-alpha/gamma agonists, or glitazars, is presently uncertain following concerns about their safety.In conclusion, several new classes of drugs have recently become available in some countries that offer new options for treating type 2 diabetes. Beneficial or neutral effects on bodyweight are an attractive feature of the new drugs. However, the higher cost of these agents, coupled with an absence of long-term safety and clinical outcome data, need to be taken into consideration by clinicians and healthcare organizations.

References

  1. Diabet Med. 1999 Mar;16(3):179-92 - PubMed
  2. Annu Rev Med. 2006;57:265-81 - PubMed
  3. Diabetes. 2007 May;56(5):1475-80 - PubMed
  4. Lancet. 2008 Mar 29;371(9618):1073-84 - PubMed
  5. Lancet. 2007 Nov 17;370(9600):1687-97 - PubMed
  6. Diabetologia. 2005 Sep;48(9):1700-13 - PubMed
  7. Lancet. 2005 Apr 16-22;365(9468):1389-97 - PubMed
  8. Lancet. 2005 Apr 16-22;365(9468):1415-28 - PubMed
  9. Nat Clin Pract Endocrinol Metab. 2007 Mar;3(3):270-8 - PubMed
  10. Diabetes Care. 2002 Dec;25(12):2244-8 - PubMed
  11. Diabetologia. 2002 Jul;45(7):S13-7 - PubMed
  12. Diabetologia. 2006 Sep;49(9):2049-57 - PubMed
  13. Lancet. 2007 May 26;369(9575):1823-31 - PubMed
  14. J Clin Endocrinol Metab. 2000 Nov;85(11):4053-9 - PubMed
  15. Lancet. 2006 Nov 11;368(9548):1660-72 - PubMed
  16. J Clin Invest. 2000 Aug;106(4):453-8 - PubMed
  17. Diabetes Care. 2005 Jan;28(1):154-63 - PubMed
  18. Horm Metab Res. 2004 Nov-Dec;36(11-12):842-5 - PubMed
  19. Diabetes Obes Metab. 2007 Nov;9(6):781-91 - PubMed
  20. Adv Pharmacol. 2005;52:99-121 - PubMed
  21. Curr Med Res Opin. 2004 Apr;20(4):565-72 - PubMed
  22. N Engl J Med. 2005 Jan 13;352(2):174-83 - PubMed
  23. Trends Pharmacol Sci. 2004 Feb;25(2):86-91 - PubMed
  24. JAMA. 2006 Feb 15;295(7):826-8 - PubMed
  25. Diabet Med. 2008 Aug;25 Suppl 2:2-8 - PubMed
  26. N Engl J Med. 2005 Jul 21;353(3):300-2 - PubMed
  27. Diabetologia. 2004 Mar;47(3):575-580 - PubMed
  28. J Clin Endocrinol Metab. 2001 Jul;86(7):3257-65 - PubMed
  29. Diabetes Care. 2006 Dec;29(12):2638-43 - PubMed
  30. Diabetes Care. 2007 Jun;30(6):1487-93 - PubMed
  31. Diabet Med. 2007 Mar;24(3):223-32 - PubMed
  32. Drugs Aging. 2000 Nov;17(5):411-25 - PubMed
  33. Curr Diab Rep. 2003 Oct;3(5):365-72 - PubMed
  34. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006060 - PubMed
  35. Diabetologia. 2001 Sep;44(9):1118-20 - PubMed
  36. Clin Ther. 2006 Oct;28(10):1556-68 - PubMed
  37. Drug Saf. 2007;30(12):1127-42 - PubMed
  38. Drugs. 2005;65(3):385-411 - PubMed
  39. J Biol Chem. 1992 Apr 15;267(11):7402-5 - PubMed
  40. Ann Intern Med. 1999 Mar 2;130(5):389-96 - PubMed
  41. Diabetes. 2005 Jan;54(1):146-51 - PubMed
  42. Diabetes Care. 2005 May;28(5):1092-100 - PubMed
  43. J Clin Endocrinol Metab. 2002 Mar;87(3):1239-46 - PubMed
  44. N Engl J Med. 1993 Jun 10;328(23):1676-85 - PubMed
  45. Drugs. 2002;62(10 ):1463-80 - PubMed
  46. Diabetes Care. 2006 Mar;29(3):510-4 - PubMed
  47. Curr Med Res Opin. 2008 Jan;24(1):275-86 - PubMed
  48. Lancet. 2002 Jun 15;359(9323):2072-7 - PubMed
  49. J Clin Endocrinol Metab. 2008 Jan;93(1):103-9 - PubMed
  50. Lancet. 2007 Nov 17;370(9600):1671-2 - PubMed
  51. Diabetes Care. 2007 Jun;30(6):1608-10 - PubMed
  52. Diabetes Obes Metab. 1999 Jan;1(1):13-22 - PubMed
  53. N Engl J Med. 2008 Feb 7;358(6):580-91 - PubMed
  54. JAMA. 2008 Apr 2;299(13):1561-73 - PubMed
  55. Lancet. 2007 Nov 17;370(9600):1706-13 - PubMed
  56. Curr Diab Rep. 2006 Jun;6(3):194-201 - PubMed
  57. N Engl J Med. 2003 Jan 30;348(5):383-93 - PubMed
  58. Diabetes Care. 2005 Aug;28(8):1936-40 - PubMed
  59. J Clin Endocrinol Metab. 2007 Nov;92(11):4165-71 - PubMed
  60. Diabetes Metab. 2003 Sep;29(4 Pt 2):6S44-52 - PubMed
  61. Diabetologia. 2004 Feb;47(2):157-69 - PubMed
  62. Treat Endocrinol. 2005;4(6):361-70 - PubMed
  63. Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):587-605 - PubMed
  64. Lancet. 1998 Sep 12;352(9131):854-65 - PubMed
  65. Ann Intern Med. 2005 Oct 18;143(8):559-69 - PubMed
  66. Lancet. 1998 Sep 12;352(9131):837-53 - PubMed
  67. Clin Ther. 2006 May;28(5):652-65 - PubMed
  68. Lancet. 2001 Jun 9;357(9271):1870-5 - PubMed
  69. N Engl J Med. 2004 Sep 9;351(11):1106-18 - PubMed
  70. Diabetes Care. 2007 Nov;30(11):2767-72 - PubMed
  71. N Engl J Med. 2008 Sep 11;359(11):1092-5 - PubMed
  72. Br J Clin Pharmacol. 2008 Mar;65(3):338-46 - PubMed
  73. Diabetologia. 2006 Feb;49(2):253-60 - PubMed
  74. Expert Opin Investig Drugs. 2008 Jan;17(1):105-13 - PubMed
  75. Nature. 2001 Dec 13;414(6865):821-7 - PubMed
  76. N Engl J Med. 2008 Jun 12;358(24):2545-59 - PubMed
  77. Clin Ther. 2007 Nov;29(11):2333-48 - PubMed
  78. Clin Ther. 2005 Oct;27(10):1500-12 - PubMed
  79. Diabetes Obes Metab. 2008 Nov;10(11):1114-24 - PubMed
  80. N Engl J Med. 2005 Nov 17;353(20):2121-34 - PubMed
  81. Expert Opin Investig Drugs. 2007 Feb;16(2):231-7 - PubMed
  82. Expert Opin Pharmacother. 2006 Jun;7(8):1055-64 - PubMed
  83. Ann Pharmacother. 2007 Dec;41(12):2014-8 - PubMed
  84. Expert Opin Emerg Drugs. 2006 Sep;11(3):525-39 - PubMed
  85. N Engl J Med. 2007 Jul 5;357(1):67-9 - PubMed
  86. Diabetes Obes Metab. 2008 Dec;10(12):1221-38 - PubMed
  87. Horm Metab Res. 2006 Jun;38(6):423-8 - PubMed
  88. Diabetes Care. 2004 May;27(5):1047-53 - PubMed
  89. Diabetes Care. 2007 Apr;30(4):890-5 - PubMed
  90. Nat Rev Drug Discov. 2006 Apr;5(4):295-309 - PubMed
  91. Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):657-85 - PubMed
  92. Horm Metab Res. 2002 Sep;34(9):504-8 - PubMed
  93. Expert Opin Pharmacother. 2007 Oct;8(15):2593-608 - PubMed
  94. BMJ. 2000 Jul 29;321(7256):252-3 - PubMed
  95. Diabet Med. 2005 Aug;22(8):963-72 - PubMed
  96. Ann Intern Med. 2007 Apr 3;146(7):477-85 - PubMed
  97. Diabetologia. 2006 Nov;49(11):2564-71 - PubMed
  98. JAMA. 2001 May 16;285(19):2486-97 - PubMed
  99. JAMA. 2007 Jul 11;298(2):194-206 - PubMed
  100. J Clin Invest. 2006 Mar;116(3):581-9 - PubMed
  101. Lancet. 2007 Sep 29;370(9593):1129-36 - PubMed
  102. Diabetologia. 2006 May;49(5):930-6 - PubMed
  103. N Engl J Med. 1996 Feb 29;334(9):574-9 - PubMed
  104. Diabetes Obes Metab. 2007 Sep;9(5):640-7 - PubMed
  105. Lancet. 2008 Oct 4;372(9645):1240-50 - PubMed
  106. Endocr Pract. 2006 Jan-Feb;12 Suppl 1:142-7 - PubMed
  107. N Engl J Med. 2007 Jul 5;357(1):28-38 - PubMed
  108. Diabetes Metab. 2007 Feb;33(1):3-12 - PubMed
  109. Diabetologia. 2007 Feb;50(2):259-67 - PubMed
  110. Diabetes Care. 2004 Jun;27(6):1335-42 - PubMed
  111. Diabetologia. 2004 Sep;47(9):1519-27 - PubMed
  112. Curr Atheroscler Rep. 2006 Sep;8(5):397-404 - PubMed
  113. Curr Opin Endocrinol Diabetes Obes. 2007 Aug;14(4):269-76 - PubMed
  114. Diabetologia. 2006 Mar;49(3):442-51 - PubMed
  115. N Engl J Med. 2008 Jun 12;358(24):2560-72 - PubMed
  116. Endocrinol Metab Clin North Am. 2005 Mar;34(1):155-97 - PubMed
  117. Diabetes Technol Ther. 2006 Jun;8(3):385-96 - PubMed
  118. Diabetes. 2005 Apr;54(4):1150-6 - PubMed
  119. Nat Rev Drug Discov. 2004 Sep;3(9):771-84 - PubMed
  120. Circulation. 2004 Mar 2;109(8):962-5 - PubMed
  121. Trends Endocrinol Metab. 2004 May-Jun;15(4):158-65 - PubMed
  122. Curr Cardiol Rep. 2007 May;9(3):167-9 - PubMed
  123. Arterioscler Thromb Vasc Biol. 2001 Mar;21(3):295-6 - PubMed
  124. Diabetologia. 2006 Mar;49(3):434-41 - PubMed
  125. N Engl J Med. 2007 Aug 30;357(9):844-6 - PubMed
  126. N Engl J Med. 2007 Oct 25;357(17):1716-30 - PubMed
  127. Diabetes Care. 2008 Jan;31(1):30-5 - PubMed
  128. N Engl J Med. 2008 Jan 17;358(3):293-7 - PubMed
  129. Lancet. 2001 Nov 17;358(9294):1709-16 - PubMed
  130. Diabetes. 1999 Jan;48(1):86-93 - PubMed
  131. Diabetes Obes Metab. 2007 Sep;9(5):733-45 - PubMed
  132. JAMA. 2006 Feb 15;295(7):761-75 - PubMed
  133. J Clin Pharmacol. 2008 May;48(5):592-8 - PubMed
  134. Drug Saf. 1994 Oct;11(4):223-41 - PubMed
  135. Diabet Med. 2005 Aug;22(8):1016-23 - PubMed
  136. Lancet. 2005 Oct 8;366(9493):1241-2 - PubMed
  137. Cardiovasc Drugs Ther. 2005 Jan;19(1):9-11 - PubMed
  138. Obes Rev. 2007 Sep;8(5):381-4 - PubMed
  139. Lancet. 2006 Nov 11;368(9548):1696-705 - PubMed
  140. N Engl J Med. 2008 Jun 12;358(24):2630-3 - PubMed
  141. Endocrinol Metab Clin North Am. 2001 Dec;30(4):1011-30 - PubMed
  142. J Med Chem. 2004 Aug 12;47(17):4135-41 - PubMed
  143. Curr Med Res Opin. 2008 Jan;24(1):79-85 - PubMed
  144. Horm Metab Res. 2007 Nov;39(11):826-9 - PubMed
  145. Diabetes Care. 2008 Jan;31(1):173-5 - PubMed
  146. Endocrinology. 2004 Jun;145(6):2653-9 - PubMed
  147. Diabetes Metab Res Rev. 2000 Mar-Apr;16(2):125-32 - PubMed
  148. Nat Med. 2004 Apr;10(4):355-61 - PubMed
  149. Curr Med Res Opin. 2008 Feb;24(2):401-17 - PubMed
  150. Diabetologia. 2007 Jun;50(6):1148-55 - PubMed
  151. Diabetes Metab. 1998 Sep;24(4):311-20 - PubMed
  152. Lancet. 2006 Sep 23;368(9541):1096-105 - PubMed
  153. N Engl J Med. 2008 Oct 9;359(15):1577-89 - PubMed
  154. Nephron Clin Pract. 2005;100(4):c120-5 - PubMed
  155. J Clin Endocrinol Metab. 2004 Aug;89(8):3629-43 - PubMed
  156. Am J Med. 2005 May;118 Suppl 5A:14S-20S - PubMed
  157. Exp Clin Endocrinol Diabetes. 2006 Feb;114(2):75-81 - PubMed
  158. Am J Physiol Endocrinol Metab. 2006 Jul;291(1):E175-81 - PubMed
  159. Curr Opin Cardiol. 2006 Jan;21(1):1-6 - PubMed
  160. Am J Cardiol. 2007 Jun 18;99(12A):34i-43i - PubMed
  161. J Clin Endocrinol Metab. 2001 Mar;86(3):1306-12 - PubMed
  162. Diabetes Obes Metab. 2007 Mar;9(2):194-205 - PubMed
  163. Expert Opin Investig Drugs. 2006 Mar;15(3):205-10 - PubMed
  164. Diabet Med. 2006 Mar;23(3):240-5 - PubMed
  165. J Clin Endocrinol Metab. 2008 Feb;93(2):459-64 - PubMed
  166. Ann Intern Med. 2006 Jul 18;145(2):125-34 - PubMed
  167. Drugs Today (Barc). 2006 Mar;42(3):139-46 - PubMed
  168. Diabetologia. 2005 Dec;48(12):2454-9 - PubMed
  169. Am J Med. 2003 Dec 8;115 Suppl 8A:20S-23S - PubMed
  170. Diabetes Care. 1999 Jun;22(6):960-4 - PubMed
  171. Drug Saf. 1999 Jul;21(1):7-22 - PubMed
  172. Eur J Clin Invest. 2004 Aug;34(8):535-42 - PubMed
  173. J Clin Endocrinol Metab. 2003 Jun;88(6):2422-9 - PubMed
  174. JAMA. 2008 Jan 23;299(3):316-23 - PubMed
  175. Diabetes Care. 2004 Dec;27(12):2874-80 - PubMed
  176. Pharmacotherapy. 2005 Jun;25(6):803-9 - PubMed
  177. Int J Clin Pract. 2006 Nov;60(11):1454-70 - PubMed
  178. Diabetes Obes Metab. 2008 May;10(5):376-86 - PubMed
  179. Diabetes Obes Metab. 2008 Nov;10(11):1047-56 - PubMed
  180. N Engl J Med. 2007 Jun 14;356(24):2457-71 - PubMed
  181. Diabetes Care. 2003 Mar;26(3):886-91 - PubMed
  182. Diabetologia. 2005 May;48(5):838-48 - PubMed
  183. JAMA. 2008 Apr 2;299(13):1547-60 - PubMed
  184. BMJ. 2008 Mar 1;336(7642):458-9 - PubMed
  185. JAMA. 1999 Jun 2;281(21):2005-12 - PubMed
  186. Lancet. 2006 Jul 1;368(9529):29-36 - PubMed
  187. N Engl J Med. 2007 Aug 23;357(8):753-61 - PubMed
  188. Treat Endocrinol. 2006;5(4):201-10 - PubMed
  189. Am J Med Sci. 2006 May;331(5):257-63 - PubMed
  190. J Clin Endocrinol Metab. 2004 Jun;89(6):2728-35 - PubMed
  191. J Cardiovasc Risk. 2003 Apr;10(2):121-8 - PubMed
  192. Curr Diab Rep. 2007 Apr;7(2):114-22 - PubMed
  193. Endocrinology. 2001 Feb;142(2):521-7 - PubMed
  194. Diabetes Metab. 2006 Apr;32(2):113-20 - PubMed
  195. Atheroscler Suppl. 2006 Apr;7(1):43-9 - PubMed
  196. Diabetes Care. 2006 Aug;29(8):1963-72 - PubMed
  197. Circulation. 2006 Jun 27;113(25):2914-8 - PubMed
  198. Lancet. 2005 Apr 9-15;365(9467):1333-46 - PubMed
  199. JAMA. 2005 Nov 23;294(20):2581-6 - PubMed
  200. N Engl J Med. 2006 Dec 7;355(23):2427-43 - PubMed
  201. Cell Metab. 2008 Jan;7(1):68-78 - PubMed
  202. Am J Manag Care. 2006 Aug;12(8):435-40 - PubMed

Substances

MeSH terms

Publication Types